论文部分内容阅读
目的观察并探讨尿激酶在急性心肌梗塞的治疗中的应用效果。方法选取100例急性心肌梗塞患者,依据治疗方法的不同将其列入观察组与对照组,每组各为50例。对照组使用克赛行常规治疗,观察组则使用尿激酶进行静脉溶栓治疗,观察两组患者的临床疗效。结果两组溶栓再通率、再梗塞率和死亡率比较,观察组均显著优于对照组,差异均具有统计学意义(P<0.05);两组均不存在明显的不良反应。结论在急性心肌梗塞的治疗中,尿激酶安全有效,可推广使用。
Objective To observe and explore the application of urokinase in the treatment of acute myocardial infarction. Methods 100 patients with acute myocardial infarction were selected according to the different treatment methods were included in the observation group and control group, each group of 50 cases. The control group used routine treatment of Ketai line, while the observation group used intravenous thrombolytic therapy with urokinase to observe the clinical efficacy of the two groups. Results The reperfusion rate, reinfarction rate and mortality of the two groups were significantly better than those of the control group (P <0.05). There was no significant adverse reaction in both groups. Conclusion In the treatment of acute myocardial infarction, urokinase is safe and effective and can be widely used.